LTFS
NAGE

Ladenburg Thalmann Financial Services’s Niagen Bioscience NAGE Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,754
Closed -$11K – 4967
2016
Q3 		$11K Hold
3,754
– – ﹤0.01% 3773
2016
Q2 		$16K Buy
+3,754
New +$17.8K ﹤0.01% 3498

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Ladenburg Thalmann Financial Services's NAGE Position: Q4 2016 in Review

Ladenburg Thalmann Financial Services sold out of Niagen Bioscience (NAGE) in Q4 2016, closing a stake of 3,754 shares — an estimated $11K sold.

Ladenburg Thalmann Financial Services first reported a position in NAGE in Q2 2016 and held it in 2 quarters. The position peaked at $16K in Q2 2016. 52 funds tracked by Wall St. Rank hold NAGE as of Q4 2016.

  • Ladenburg Thalmann Financial Services reported no remaining Niagen Bioscience position as of Q4 2016 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 3,754 Niagen Bioscience shares in Q4 2016, an estimated $11K.
  • Ladenburg Thalmann Financial Services first reported a position in Niagen Bioscience in Q2 2016 and held it in 2 quarters.
  • Ladenburg Thalmann Financial Services's Niagen Bioscience position peaked at $16K in Q2 2016.
  • 52 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2016.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2016, filed 14 Feb 2017.